Anti-PD-1/PD-L1 mAbs have not only shown long-lasting beneficial responses in patients with a broad range of human cancers, but also displayed reduced toxicity compared with other ICIs, such as anti-CTLA-4 mAbs (16). The gene discussed is PDCD1; the disease is cancer.